DSTN protein has been proposed as a potential biomarker and regulatory protein for AD protection with Rb1 pretreatment (Hwang et al., 2016); Glycogen Synthase (GYS), belonging to the GT3 superfamily, is classified as a retaining glycosyltransferase (GT). This evidence concerns the gene DSTN and Alzheimer disease.